Overview

Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

Status:
Unknown status
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Axcan Pharma
Treatments:
Ursodeoxycholic Acid